Trastuzumab inn trastuzumab or trastuzumab deruxtecan). Herceptin is a medicine that contains the active substance trastuzumab. The second is confusion between conjugates containing the same substance but coupled to different active moieties, such as between anvatabart opadotin and anvatabart pactil, and trastuzumab imbotolimod, trastuzumab rezetecan and the other four trastuzumab-drug conjugates that have already been named, at least one of which is already marketed (b). The reference medicine for Tuznue is Herceptin. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. [11][12] It is licensed for the treatment of breast cancer, non-small cell lung cancer (NSCLC TRASTUZUMAB ANNS [WHO-DD] TRASTUZUMAB BETA TRASTUZUMAB BETA [INN] TRASTUZUMAB BIOSIMILAR (ABP-980) TRASTUZUMAB BIOSIMILAR (AMGEN) TRASTUZUMAB BIOSIMILAR (CELLTRION) TRASTUZUMAB BIOSIMILAR (CT-P6) TRASTUZUMAB BIOSIMILAR (MYL-1401O) TRASTUZUMAB BIOSIMILAR (MYLAN GMBH) TRASTUZUMAB BIOSIMILAR (PFIZER) TRASTUZUMAB BIOSIMILAR (SB-3) TRASTUZUMAB DKST Trastuzumab is a humanized monoclonal antibody to the human epidermal growth factor receptor 2 (HER2) which is used in combination with other antineoplastic agents in the therapy of breast and gastric cancer. Binding of trastuzumab to HER2 inhibits ligand-independent HER2 signalling and prevents the proteolytic cleavage of its extracellular domain, an activation mechanism of HER2. as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel as part of a treatment regimen with docetaxel and carboplatin as a single agent following multi HERCEPTIN® (trastuzumab) for injection, for intravenous use Initial U. It’s also known by other names such as Herceptin, Herzuma and Ontruzant. Figure 1. You pronounce it as tras-too-zoo-mab. Oct 1, 2025 · Trastuzumab injection is also used in combination with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic (cancer that has spread) stomach and gastroesophageal (stomach and esophagus) cancer. Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. Trastuzumab blocks the activity of HER2 and triggers a type of immune reaction that kills cells that have a lot of HER2. It is a ‘biosimilar medicine’. This activity outlines trastuzumab's various indications and off-label uses, including its combination with anthracycline or taxane-based chemotherapy for breast cancer, as monotherapy or in combination with paclitaxel for metastatic breast cancer, and in combination with cisplatin Apr 29, 2025 · Trastuzumab: side effects, dosage, interactions, FAQs, reviews. By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the cancer cells. 5-fold, when administered in combination with paclitaxel as compared to trough 475 concentrations of trastuzumab when administered in combination with an anthracycline and 476 cyclophosphamide. Trastuzumab was originally approved as an intravenous (IV) formulation but has The key findings related to trastuzumab history are summarized in Figure 1. After demonstrating the clinical benefits of trastuzumab, many studies were carried out in an attempt to unravel the mechanisms of action of trastuzumab. Esta información de Lexicomp® le explica lo que debe saber sobre este medicamento, por ejemplo, para qué se usa, cómo tomarlo, sus efectos secundarios y cuándo llamar a su proveedor de cuidados de la salud. This activity outlines trastuzumab's various indications and off-label uses, including its combination with anthracycline or taxane-based chemotherapy for breast cancer, as monotherapy or in … International Nonproprietary Names for Pharmaceutical Substances (INN) Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Trastuzumab Trastuzumab is a targeted cancer drug. Rec. Ontruzant will be available as a 150 mg powder for concentrate for solution for infusion. Approval: 1998 WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Trastuzumab is a monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Your cancer cells can be tested to see if trastuzumab is a possible medicine for you. Feb 8, 2021 · The active substance in Enhertu, trastuzumab deruxtecan, is made up of two active components which are linked together: trastuzumab is a monoclonal antibody (a type of protein) that has been designed to attach to HER2. R9); Resolution EB115. Trastuzumab has been implicated in causing instances of transient serum enzyme elevations, but has only rarely been linked to instances of clinically apparent liver injury with jaundice We would like to show you a description here but the site won’t allow us. It is available as a powder to be made up into a solution for infusion (drip) into a vein or as a solution for injection under the skin. Jun 22, 2024 · Trastuzumab is an FDA-approved antineoplastic biologic that targets HER2-positive breast and gastric cancer. INN ATC (Anatomical Therapeutic Chemical Classification) L01XC03 CAS registry number (Chemical Abstracts Service) 0180288-69-1 Chemical Formula C6470-H10012-N1726-O2013-S42 Therapeutic Categories for ENHERTU. Trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, and trastuzumab-qyyp are considered to be "biosimilar" to trastuzumab injection which means they work just as well and are just as safe to use as trastuzumab injection. value}} Al fine di evitare errori con il medicinale, è importante verificare le etichette dei flaconcini per assicurarsi che il medicinale che si sta preparando e somministrando sia Enhertu (trastuzumab deruxtecan) e non trastuzumab o trastuzumab emtansine. ENHERTU® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U. R7); 1969, 173, 10 (Resolution EB43. Wld Health Org. How is Tuznue used? Jul 5, 2007 · Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. The active substance of Enhertu is trastuzumab deruxtecan, a monoclonal antibody-drug conjugate (ATC code: L01XC41) that binds to the human epidermal growth factor receptor 2 (HER2), disrupting HER2 signalling and also mediating antibody-dependent cell-mediated cytotoxicity. Jul 21, 2022 · INN and Biologicals INN stems INN Lists INN Notes INN Schemes INN Collaborations INN online application Trastuzumab emtansine, [6][7] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. The active substance of Ontruzant is trastuzumab, a monoclonal antibody (ATC code: L01XC03) that binds with high affinity and specificity to HER2 leading to the inhibition of the proliferation of tumour cells that overexpress HER2. Trastuzumab prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. g. » Japanese version » Back DBGET Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) that contains a humanised anti-HER2 IgG1 monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, produced by mammalian (Chinese Hamster Ovary) cells, covalently linked to DXd, an exatecan derivative and a topoisomerase I inhibitor, via a tetrapeptide-based cleavable » Japanese version » BackDBGET integrated database retrieval system During the 63rd INN Consultation in 2016, an INN-USAN-harmonized nomenclature scheme for substances for cell-based gene therapy was formally approved by the members of the INN Expert Group designated with the selection of international nonproprietary names4. Trastuzumab is a treatment for: breast cancer – for early breast cancer , locally advanced breast cancer and secondary breast cancer advanced stomach cancer advanced cancer of where the food pipe joins your stomach (gastro » Japanese version » BackDBGET integrated database retrieval system Enhertu will be available as 100 mg powder for concentrate for solution for infusion. Nov 27, 2024 · Trastuzumab stops the growth and development of cancer cells that express large amounts of a protein called HER2. Rituximab or Trastuzumab BTPs, or their corresponding SBPs, that have been approved by stringent regulatory authorities (SRA) and marketed in the country of registration; and which will be assessed via an Abridged Assessment pathway. It is a type of targeted therapy drug called a monoclonal antibody. In this review, we discuss different mechanisms of action proposed for trastuzumab. Adjuvant Breast Cancer: Trastuzumab is indicated for adjuvant treatment of HER2 overexpressing node-positive or node-negative ER/PR negative or with one high-risk feature breast cancer. R4 (EB115/2005/REC/1)], the following names are . It is used to treat advanced or metastatic breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane (type of cancer medicine). Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Enhertu non deve essere sostituito con trastuzumab o trastuzumab emtansine. DRUG: Trastuzumab » Japanese version » Back Chemical substance (2) PubChem (1) NIKKAJI (1) All databases (2) Download RDF DRUG: Trastuzumab emtansine Oct 20, 2025 · Herceptin Active substance trastuzumab International non-proprietary name (INN) or common name trastuzumab Therapeutic area (MeSH) Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). Dec 19, 2013 · Kadcyla is a cancer medicine that contains the active substance trastuzumab emtansine. Trastuzumab binds with high affinity and specificity to sub-domain IV, a juxta-membrane region of HER2’s extracellular domain. Trastuzumab injection mentioned in the monograph below refers to any of these 7 products. Trastuzumab, a humanized monoclonal antibody that targets HER2 10 { {acid. RECOMMENDED International Nonproprietary Names: List 86 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. value}} { {acid. In addition, after binding 472 7 DRUG INTERACTIONS 473 In Study 5, the mean serum trough concentration of trastuzumab was consistently elevated 474 approximately 1. S. [8][9][10][11] Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine Dec 9, 2016 · the list on the following pages are under consideration by the World Health Organization as Proposed Tuznue contains the active substance trastuzumab and is a biological medicine. [31][28][32][33] It is specifically used for cancer that is HER2 receptor positive. Trastuzumab also stops HER2 from stimulating the growth of cancer cells Comment: Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2. US matches: Trastuzumab Trastuzumab and hyaluronidase-oysk Trastuzumab-anns Trastuzumab-dkst Trastuzumab-dttb Trastuzumab-pkrb Scheme Rec. This means that Tuznue is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. Approval: 2019 WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. , 1955, 60, 3 (Resolution EB15. Used for: breast cancer, breast cancer, adjuvant, breast cancer, metastatic, esophageal carcinoma, and Trastuzumab works by binding to HER2, a protein found in high levels on some cancer cells and causes them to grow. Kadcyla can only be used when the cancer has been shown to ‘overexpress HER2’: this means that the cancer cell » Japanese version » BackDBGET integrated database retrieval system In order to prevent medicinal product errors it is important to check the vial labels to ensure that the medicinal product being prepared and administered is Kadcyla (trastuzumab emtansine) and not another trastuzumab-containing product (e. [31] Jun 22, 2024 · Trastuzumab is an FDA-approved antineoplastic biologic that targets HER2-positive breast and gastric cancer. rojrsvacd4mw6wvnavmomg6tb7s0y7cgyw2sejc9fvu1yqaryv0i